Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytek Biosciences Inc (NQ: CTKB )

4.740 -0.750 (-13.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences Inc

< Previous 1 2 3 4 Next >
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Cytek Biosciences
Via Benzinga
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023
CTKB stock results show that Cytek Biosciences beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
New System Saves Time and Resources, Improves Efficiency and Accuracy 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says
Stephens initiated coverage on Cytek Biosciences Inc (NASDAQ: CTKB), a manufacturer and supplier of flow cytometry products and services.  
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Cytek Biosciences Reports Third Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.